Is Prostate Specific Antigen Velocity Selective For Clinically Significant Prostate Cancer In Screening?
May 15th 2008Drug InformationProstate
UroToday.com - With the knowledge that screening for prostate cancer will lead to over detection and subsequent over treatment, the call for tests discriminating between non aggressive and aggressive prostate cancer is growing. If pre-biopsy data could make this distinction, a lot of unnecessary biopsies would be spared. The amount of prostate cancer specific antigen (PSA) increase in a year, PSA velocity (PSAV), has been suggested as a factor predictive for aggressive disease.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
